Plasma total cholesterol (TC) (8), triglyceride (TG) (9), low-density lipoprotein cholesterol (LDL-C) (10), apolipoprotein (Apo) B (11), high-density lipoprotein cholesterol (HDL-C) (12), ApoA1 and the ApoA1/ApoB ratio (13) are traditionally monitored as predictors of dyslipidemia and also the main target for therapeutic intervention, by regulating blood lipid control (14). This evidence concerns the gene APOB and metabolic syndrome.